详情页

资源类型：

文章类型：

作者：

Li, Huiping[8] * ; Jiang, Hanfang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Yin, Yongmei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Tong, Zhongsheng[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Ouyang, Quchang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Shen, Kunwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Yuan, Zhongyu[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Geng, Cuizhi[8]

; Ran, Ran[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhang, Ruyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Liu, Ya-Xin[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhang, Jiayang[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Li, Wei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Qu, Qing[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhou, Qiaoxia[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Dong, Xunwei[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Meng, Luping[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Zhu, Xiaoyan[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Yi, Zhen[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ; Tong, Youzhi[1,2,3,4,5,6,7,8,9,10,11,12,13,14,15] ;

机构： [1]Beijing Cancer Hospital, Beijing, China [2]Peking University Cancer Hospital, Beijing, China [3]Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China [4]Department of Medical Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China [5]Department of Medical Oncology, Hunan Cancer Hospital, Changsha, Hunan, China [6]Comprehensive Breast Health Center, Shanghai Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [7]Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China [8]Fourth Hospital of Hebei Medical University, Shijiazhuang, China [9]Department of Breast Oncology, Peking University Cancer Hospital and Cancer Institute, Beijing, China [10]Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, China [11]Department of Breast Oncology, Peking University Cancer Hospital, Beijing, China [12]The First Afïliated Hospital of Nanjing Medical University, Nanjing, China [13]Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China [14]Kintor Pharmaceutical Limited, Suzhou, China [15]Suzhou Kintor Pharmaceuticals Inc, Suzhou, China

出处：

DOI：

ISSN：

基金：

语种：

被引次数：

WOS：

中科院分区：

出版当年[2021]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

最新[2025]版：

大类 | 1 区

医学

小类 | 1 区肿瘤学

JCR分区：

出版当年[2021]版：

Q1 ONCOLOGY

最新[2024]版：

Q1 ONCOLOGY

第一作者：

第一作者机构： [8]Fourth Hospital of Hebei Medical University, Shijiazhuang, China

推荐引用方式(GB/T 7714)：

APA：

MLA：

A phase Ib study of proxalutamide (GT0918) in women with androgen receptor-positive metastatic breast cancer.

文献详情